Pro-Con: Antiobesity Drugs Such as Glucagon-Like Peptide-1 Receptor Agonists Should Be a First-Line Treatment in Idiopathic Intracranial Hypertension
In this Pro-Con piece, our authors tackle the question of whether or not antiobesity drugs (glucagon-like peptide-1 receptor agonists) should be the new first-line treatment in Idiopathic Intracranial Hypertension (IIH).
Authors
- Lisa J. Hill (ORCID: https://orcid.org/0000-0001-8431-7029)
- Aroucha Vickers (ORCID: https://orcid.org/0000-0002-4868-446X)
- Susan P. Mollan
- Andrew G. Lee
- James Mitchell
- Maria G. Lange
- Alexandra J. Sinclair
Institutions
- Cornell University (US)
- NIHR Surgical Reconstruction and Microbiology Research Centre (GB)
Publication Details
- Journal
- Journal of Neuro-Ophthalmology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1097/wno.0000000000002431
- Primary Topic
- Cerebral Venous Sinus Thrombosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00